Comparative Pharmacology
Head-to-head clinical analysis: EFFIENT versus TICLID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFFIENT versus TICLID.
EFFIENT vs TICLID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prasugrel is a thienopyridine prodrug that irreversibly inhibits the P2Y12 receptor on platelets, reducing ADP-mediated platelet aggregation.
Ticlopidine is a thienopyridine ADP receptor antagonist that irreversibly inhibits the P2Y12 receptor on platelets, preventing ADP-induced platelet aggregation.
Loading dose: 60 mg orally once. Maintenance: 10 mg orally once daily. In patients weighing <60 kg, maintenance dose is 5 mg orally once daily.
250 mg orally twice daily
None Documented
None Documented
The terminal elimination half-life of the active metabolite is about 7.6 hours (range 2-15 hours). Clinically, this supports once-daily dosing.
Terminal elimination half-life is approximately 30-50 hours (mean ~33 hours), with clinical effects lasting 7-10 days after discontinuation due to irreversible platelet binding.
Approximately 68% of the dose is excreted in urine as inactive metabolites, and about 27% in feces.
Primarily hepatic metabolism; 60% renal as metabolites, 23% fecal. Minimal parent drug excreted unchanged.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent